Association of Intergenic and Intragenic <i>MGMT</i> Enhancer Methylation with <i>MGMT</i> Promoter Methylation, MGMT Protein Expression and Clinical and Demographic Parameters in Glioblastoma.

ABSTRACT: The methylation status of the MGMT gene promoter is recognized as a key predictive biomarker for glioblastoma patients, influencing treatment decisions and outcomes. Emerging evidence suggests that enhancer methylation may also play a role in gene regulation and is associated with various clinical parameters, genetic variants, and demographic factors. This study aimed to assess DNA methylation levels in intergenic and intragenic MGMT enhancers to investigate their relationship with MGMT promoter methylation, MGMT protein expression, and clinical and demographic characteristics in glioblastoma. We developed 18 pyrosequencing assays to analyze 54 CpGs, including 34 in intergenic and 20 in intragenic enhancers. The assays were applied to tumor cells derived from 38 glioma

SUBMITTER: Puhringer K 

PROVIDER: S-EPMC11990025 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature